Who owns Akebia Therapeutics?
- Ticker: AKBA
- CUSIP Number: 00972d105
Tip: Access positions for across all investors
Analyze quarterly positions in Akebia Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Akebia Therapeutics stock
Who bought or sold Akebia Therapeutics this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Satter Management | 16M | $20M | 0% | Dec 2023 |
|
| Vanguard Group | 7.6M | $9.4M | 1% | Dec 2023 |
|
| Millennium Management | 2.6M | $3.2M | -15% | Dec 2023 |
|
| Jacobs Levy Equity Management | 1.9M | $2.3M | 8% | Dec 2023 |
|
| Federated Investors | 867k | $1.1M | -10% | Dec 2023 |
|
| Assenagon Asset Management | 791k | $1.4M | 100% | Mar 2024 |
|
| Connor, Clark & Lunn Investment Management | 620k | $769k | -1% | Dec 2023 |
|
| Citadel Advisors | 434k | $538k | 139% | Dec 2023 |
|
| Citigroup | 306k | $379k | 100% | Dec 2023 |
|
| Bank of America Corporation | 223k | $276k | -1% | Dec 2023 |
|
| Sapient Capital | 200k | $366k | 0% | Mar 2024 |
|
| Two Sigma Investments | 185k | $230k | 575% | Dec 2023 |
|
| Russell Investments | 182k | $226k | -3% | Dec 2023 |
|
| Two Sigma Advisers | 167k | $207k | -4% | Dec 2023 |
|
| UBS Group | 157k | $157k | 128% | Dec 2023 |
|
| Tudor Investment Corporation | 142k | $176k | 0% | Dec 2023 |
|
| Creative Planning | 111k | $137k | 0% | Dec 2023 |
|
| Jane Street | 98k | $121k | 62% | Dec 2023 |
|
| HighTower Advisors | 96k | $119k | 1% | Dec 2023 |
|
| Orchard Capital Managment | 87k | $108k | 30% | Dec 2023 |
|
| Gts Securities | 82k | $102k | 4% | Dec 2023 |
|
| Charles Schwab Investment Management | 80k | $99k | 0% | Dec 2023 |
|
| Goldman Sachs Group | 71k | $88k | 100% | Dec 2023 |
|
| Cubist Systematic Strategies | 68k | $84k | 100% | Dec 2023 |
|
| Mirabella Financial Services | 65k | $81k | 100% | Dec 2023 |
|
| Franklin Resources | 65k | $81k | 0% | Dec 2023 |
|
| T. Rowe Price Associates | 60k | $75k | 0% | Dec 2023 |
|
| Virtu Financial | 60k | $74k | 100% | Dec 2023 |
|
| Wolverine Trading | 50k | $63k | 11% | Dec 2023 |
|
| Edmond De Rothschild Holding | 50k | $62k | 0% | Dec 2023 |
|
| Raymond James & Associates | 41k | $76k | 38% | Mar 2024 |
|
| TD Waterhouse Canada | 41k | $76k | 0% | Dec 2023 |
|
| State of Wyoming | 40k | $49k | -46% | Dec 2023 |
|
| Squarepoint Ops | 31k | $38k | 100% | Dec 2023 |
|
| Cannon Global Investment Management | 28k | $51k | 100% | Mar 2024 |
|
| Wealth Effects | 27k | $49k | -8% | Mar 2024 |
|
| Eudaimonia Partners | 26k | $48k | -3% | Mar 2024 |
|
| Compass Ion Advisors | 25k | $46k | 100% | Mar 2024 |
|
| Graham Capital Management | 24k | $29k | 100% | Dec 2023 |
|
| Mackenzie Financial | 23k | $29k | 38% | Dec 2023 |
|
| Victory Capital Management | 23k | $28k | -97% | Dec 2023 |
|
| Schonfeld Strategic Advisors | 21k | $26k | 100% | Dec 2023 |
|
| Private Advisor | 20k | $25k | 25% | Dec 2023 |
|
| Archer Investment Corp | 20k | $25k | 100% | Dec 2023 |
|
| Mercer Global Advisors | 20k | $24k | -1% | Dec 2023 |
|
| Bank of New York Mellon | 19k | $34k | -74% | Mar 2024 |
|
| Commonwealth Equity Services | 19k | $23k | 100% | Dec 2023 |
|
| Willis Johnson & Associates | 18k | $32k | 0% | Mar 2024 |
|
| James J. Burns & Company | 16k | $25k | -36% | Mar 2024 |
|
| Hrt Financial | 15k | $18k | 100% | Dec 2023 |
|
| Sykon Capital | 15k | $19k | 0% | Dec 2023 |
|
| Baird Financial | 13k | $16k | 0% | Dec 2023 |
|
| Onyx Bridge Wealth Group | 13k | $16k | 0% | Dec 2023 |
|
| Legacy Private Trust | 12k | $22k | 100% | Mar 2024 |
|
| Eagle Wealth Strategies | 12k | $20k | -40% | Mar 2024 |
|
| Two Sigma Securities | 12k | $15k | -30% | Dec 2023 |
|
| Wells Fargo & Company | 11k | $14k | 1% | Dec 2023 |
|
| Grimes & Company | 10k | $18k | 100% | Mar 2024 |
|
| RB Capital Management | 10k | $12k | 0% | Dec 2023 |
|
| Bnp Paribas Arbitrage, Snc | 8.8k | $11k | 0% | Dec 2023 |
|
| Ameliora Wealth Management | 5.6k | $10k | 100% | Mar 2024 |
|
| Rhumbline Advisers | 4.9k | $6.1k | 0% | Dec 2023 |
|
| Fifth Third Bancorp | 3.3k | $6.0k | 0% | Mar 2024 |
|
| Johnson Financial Group | 1.4k | $1.7k | 0% | Dec 2023 |
|
| CWM | 1.0k | $2.0k | 100% | Mar 2024 |
|
| Hanson McClain Advisors | 748.00 | $1.4k | 0% | Mar 2024 |
|
| Advisor Group Holdings | 739.00 | $915.990500 | 0% | Dec 2023 |
|
| Nbc Securities | 690.00 | $1.0k | 100% | Mar 2024 |
|
| Baldwin Brothers | 561.00 | $1.0k | 0% | Mar 2024 |
|
| Capital Advisors | 320.00 | $1.0k | 0% | Mar 2024 |
|
| Jpmorgan Chase & Co | 231.00 | $286.001100 | -100% | Dec 2023 |
|
| Hexagon Capital Partners | 186.00 | $340.008000 | 0% | Mar 2024 |
|
| Royal Bank of Canada | 100.00 | $0 | 100% | Dec 2023 |
|
| Focused Wealth Management | 65.00 | $81.003000 | 0% | Dec 2023 |
|
Who sold out of Akebia Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Ameritas Advisory Services | Sep 2023 | 12k | $11k |
| AdvisorNet Financial | Dec 2023 | 5.0k | $6.2k |
| PrairieView Partners | Sep 2023 | 4.0k | $4.0k |